April 23, 2026 09:18 pm (IST)
Follow us:
facebook-white sharing button
twitter-white sharing button
instagram-white sharing button
youtube-white sharing button
Bengal polls: Mob attacks central forces, 3 CAPF personnel injured in Birbhum | ‘People voting to protect their rights’: Mamata says high turnout backs TMC in Bengal | ‘Fear is being defeated’: PM Modi says high voter turnout signals BJP win in Bengal | Crude bomb attack in Murshidabad’s Nowda as violence hits Bengal polling | ‘Mamata Banerjee’s politics fuelled BJP growth in Bengal’: Rahul Gandhi | 'Will never forget’: Nation remembers Pahalgam victims as leaders vow strong fight against terror | 'India will never bow to any form of terror': PM Modi on Pahalgam terror attack anniversary | TCS Nashik case: No interim bail for Danish Shaikh in religious sentiments case | US woman alleges sexual assault at Karnataka homestay; owner among 2 arrested | ‘PM Modi is a terrorist’: Mallikarjun Kharge sparks row; BJP hits back
COVID-19
Image: PIB

Momentous feat: PM Modi after world's first DNA based anti-COVID-19 vaccine ZyCov-D gets nod

| @indiablooms | Aug 21, 2021, at 04:36 pm

New Delhi/IBNS: Prime Minister Narendra Modi has lauded the scientists after the world's first DNA based anti-COVID-19 vaccine, ZyCov-D, got approval for an emergency use in India.

The Prime Minister tweeted, "India is fighting COVID-19 with full vigour. The approval for world’s first DNA based ‘ZyCov-D’ vaccine of @ZydusUniverse is a testimony to the innovative zeal of India’s scientists. A momentous feat indeed."

Zydus Cadila Friday received approval for Emergency Use Authorization (EUA) of its COVID-19 vaccine, ZyCoV-D, from the Drug Controller General of India (DCGI) to be administered on children and adults 12 years and above.

Developed in partnership with the Department of Biotechnology, Government of India under the ‘Mission COVID Suraksha’ and implemented by BIRAC, ZyCoV-D has been supported under COVID-19 Research Consortia through National Biopharma Mission for Preclinical studies, Phase I and Phase II Clinical Trials and under the Mission COVID Suraksha for Phase III Clinical Trial.

This three-dose vaccine which when injected produces the spike protein of the SARS-CoV-2 virus and elicits an immune response, which plays a vital role in protection from disease as well as viral clearance.

The plug-and-play technology on which the plasmid DNA platform is based can be easily adapted to deal with mutations in the virus, such as those already occurring.

Support Our Journalism

We cannot do without you.. your contribution supports unbiased journalism

IBNS is not driven by any ism- not wokeism, not racism, not skewed secularism, not hyper right-wing or left liberal ideals, nor by any hardline religious beliefs or hyper nationalism. We want to serve you good old objective news, as they are. We do not judge or preach. We let people decide for themselves. We only try to present factual and well-sourced news.

Support objective journalism for a small contribution.